Difference between revisions of "Venous thromboembolism"
Jump to navigation
Jump to search
(Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' Other...") |
m (→Treatments) |
||
| Line 16: | Line 16: | ||
*[[Dabigatran (Pradaxa)]] | *[[Dabigatran (Pradaxa)]] | ||
*[[Dalteparin (Fragmin)]] | *[[Dalteparin (Fragmin)]] | ||
| + | *[[Edoxaban (Savaysa)]] | ||
*[[Enoxaparin (Lovenox)]] | *[[Enoxaparin (Lovenox)]] | ||
*[[Fondaparinux (Arixtra)]] | *[[Fondaparinux (Arixtra)]] | ||
Revision as of 17:01, 4 February 2015
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Other information on HemOnc.org regarding management of deep vein thrombosis (DVT) and pulmonary embolism (PE) include:
- Deep veins and superficial veins in the arms and legs
- Hypercoagulable state (thrombophilia) evaluation
- Compression stockings and sleeves for management and prophylaxis against postphlebitic (postthrombotic) syndrome[1]
Provoked VTE
Unprovoked VTE
Treatments
- Apixaban (Eliquis)
- Argatroban (Acova)
- Bivalirudin (Angiomax)
- Dabigatran (Pradaxa)
- Dalteparin (Fragmin)
- Edoxaban (Savaysa)
- Enoxaparin (Lovenox)
- Fondaparinux (Arixtra)
- Heparin
- Lepirudin (Refludan)
- Rivaroxaban (Xarelto)
- Tinzaparin (Innohep) (withdrawn from US market)
- Warfarin (Coumadin)
References
- ACCP Chest Guidelines - Antithrombotic Therapy and Prevention of Thrombosis, 9th edition (2012)
- Bleeding risk on anticoagulation: HAS-BLED; HEMORR2HAGES